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Introduction {#sec1}
============

Human induced pluripotent stem cells (hiPSCs) can be derived by reprogramming somatic cells from any individual. The ability to derive different cell types of the body and scale production has generated interest in their use in drug discovery, disease modeling, and regenerative medicine ([@bib27], [@bib32], [@bib34]). DNA-free reprogramming methods, where the reprogramming vectors are not integrated into the genome, are now considered to show the lowest risk of targeting important genes unintentionally. Sendai virus (SeV)-based reprogramming in particular has been widely used to generate hiPSCs from skin fibroblasts (FiPSCs), nasal epithelial cells, peripheral blood mononuclear cells (MNCs), and cells in urine (UiPSCs) ([@bib8], [@bib10], [@bib14], [@bib23]). Cells in human urine are proving of increasing interest since they can be collected non-invasively and thus from children or others preferring not to donate blood or a skin biopsy. We and others have generated endothelial cells (ECs) from hiPSC lines from these different somatic cell types, including UiPSCs ([@bib7], [@bib24], [@bib28], [@bib30], [@bib39]). However, to date there have been few direct comparisons with primary human ECs in robust assays for assessing functionality, and hiPSC-derived ECs (hiPSC-ECs) have not been compared for line-to-line and batch-to-batch variability. This has limited their utility in disease modeling and drug discovery, particularly where isogenic controls for patient lines are not available since it may be difficult to distinguish line-to-line "noise" from true, disease-related phenotypes. Furthermore, widely available human umbilical vein ECs (HUVECs) are often used in preference to hiPSC-ECs in bioassays since they are perceived as more robust, but functional comparisons are rarely made ([@bib15]). Exceptionally, we showed that the ability of HUVECs to integrate into the developing vasculature (in zebrafish) is inferior to that of hiPSC-ECs ([@bib24]). Here, we have undertaken direct side-by-side comparison of hiPSC-ECs with primary ECs, such as human dermal blood ECs (HDMECs) and HUVECs, in several widely used functional *in vitro* and *in vivo* assays. Two independent "bead-based" methods were used for hiPSC-EC isolation: CD34 + cells on day 6 of differentiation and CD31 + cells on day 10. Multiple batches of ECs were compared among a range of isogenic and non-isogenic hiPSC lines.

Barrier function was chosen as one assay that would likely be comparable across a wide set of isogenic and non-isogenic hiPSC-ECs in confluent cultures if the cells were derived in the same way. Two principal mechanisms contribute to the regulation of the EC barrier: transcellular and paracellular permeability. Paracellular permeability, or opening of inter-endothelial junctions, is linked to many pathological processes, including acute vascular leak syndrome or sepsis, acute respiratory distress syndrome, anaphylactic shock, and tumor angiogenesis. Impedance-based techniques, such as electric cell-substrate impedance sensing (ECIS), provide accurate and sensitive methods to measure endothelial barrier function, including rapid changes upon stimulation with barrier-disrupting agents, such as thrombin or histamine or known barrier-elevating agents, such as cyclic AMP ([@bib35]). Despite many reports on the generation of hPSC-ECs, only a few studies have evaluated barrier function using impedance sensing ([@bib1], [@bib28]). Here, we compared hiPSC-ECs with primary ECs in barrier function assays that included examining the disruptive effects of histamine and thrombin. These factors are known to cause transient increases in endothelial permeability, disassembly of inter-endothelial cell-cell junctions, and decrease in barrier function in primary ECs.

Secondly, inflammatory responses were examined. Heterogeneity in inflammatory responses has been reported among different vascular beds, and types of ECs ([@bib2]). ECs play essential roles in regulating inflammation by limiting leukocyte extravasation at the site of injury/inflammation, as in the case of non-inflamed/healthy endothelium, or facilitating extravasation upon local tissue injury or inflammation. The leukocyte recruitment cascade and molecular players that regulate these processes are well characterized and include pro-adhesive receptors, such as E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1). These receptors are upregulated on the EC surface and participate in capturing and "rolling" leukocytes on the vessel wall, to mediate firm adhesion ([@bib13], [@bib22]). The transmigration of leukocytes is further mediated via interplay with homotypic cell adhesion receptors, such as vascular endothelial cadherin (Ve-cadherin), junctional adhesion molecules (JAMs), EC-selective adhesion molecule (ESAM), CD99, and others ([@bib22]) that are expressed between endothelial cell-cell junctions. Chronic inflammation contributes to many different pathological conditions, such as cardiovascular and neurological and neurodegenerative disorders ([@bib27]). Uncontrolled or systemic inflammation results in severe pathological conditions such as sepsis, or adverse drug responses. Thus, careful assessment of inflammatory responses in hiPSC-ECs is needed before decisions can be made on their utility in future assays on, for example, the effects of genetic background on inflammatory responses in patient-specific hiPSC-derived tissues or regenerative medicine.

We carried out extensive assessment of hiPSC-ECs from multiple hiPSC lines and batches in all of the assays described above (barrier function, transient disruption of barrier, expression of inflammatory adhesive receptors, and leukocyte adhesion under flow) and compared them with primary ECs. Finally, angiogenic/vasculogenic responses and the ability to form functional blood vessels were compared *in vitro* and *in vivo*.

Results {#sec2}
=======

Differentiation of hiPSCs toward ECs {#sec2.1}
------------------------------------

hiPSC lines were generated using SeV ([@bib21]), ([@bib40]). For differentiation toward ECs, we used a protocol based on defined reagents without serum, as previously described ([@bib24], [@bib25]). We examined the percentages of Ve-cadherin+ (VEC+) cells on day 6 and day 10 of differentiation and found this was significantly higher on day 6 compared with day 10 ([Figure 1](#fig1){ref-type="fig"}A), in agreement with our previous findings ([@bib11], [@bib24]). In order to isolate ECs, CD34 and CD31 magnetic-bead-based purification was used on day 6 and day 10 of differentiation, respectively, as described previously ([@bib11], [@bib24], [@bib25]). ECs isolated either on day 6 or day 10 displayed typical EC-like morphology ([Figure 1](#fig1){ref-type="fig"}B). Fluorescence-activated cell sorting (FACS) analysis of CD34+ and CD31+ hiPSC-ECs revealed their comparable expression of known EC surface markers, such as VEC, CD31, CD34, VEGFR2, CXCR4, VEGFR3, CD73, and CD105 ([Figures 1](#fig1){ref-type="fig"}C and 1D). Expression of VEC, CD31, CD73, and CD105 by CD34+ and CD31+ hiPSC-ECs was also similar to that in primary HUVECs and HDMECs, while expression of CD34, CXCR4, VEGFR2, and VEGFR3 was higher. Gene expression profiling revealed a mixed arterial- and embryonic-like identity in hiPSC-ECs with prominent expression of both arterial markers, such as *VEGFR2* (*KDR*) and *SOX17*, and venous markers, such as *COUPTFII* (*NR2F2*) and *APLNR*. However, expression of other well-established arterial markers, such *NOTCH1*, *NOTCH4*, *JAG1*, *NRP1*, *CX40* (*GJA5*), and *EPHRINB2* (*EFNB2*), was lower than in human umbilical artery ECs (HUAECs) ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Immunofluorescent staining revealed inter-junctional localization of VEC, CD31, and ZO1, and intracellular von Willebrand factor (vWF) ([Figures 1](#fig1){ref-type="fig"}E and [S1](#mmc1){ref-type="supplementary-material"}B), although overall vWF levels were lower compared with primary ECs ([Figure S1](#mmc1){ref-type="supplementary-material"}B).Figure 1Differentiation of hiPSCs toward ECs(A) Representative FACS plots and quantification of the percentage of VEC+ cells at day 6 and day 10 differentiation of UiPSCs. Average %VEC+ from three independent biological replicates are shown, error bars represent ±SD. ^∗^p \< 0.05.(B) Phase-contrast images of CD34+ and CD31+ hiPSC-ECs 3 days post isolation. Scale bar represents 300 μm.(C) FACS analysis of surface marker expression on isolated CD34+ and CD31+ hiPSC-ECs at passage 2 (P2) and primary ECs (HUVECs and HDMECs at P4--P5). Black and color filled histograms are staining with the antibody of interest; light gray histograms are relevant isotype control.(D) Quantification of surface marker expression on isolated CD34+ and CD31+ hiPSC-ECs at passage 2 (P2). Median fluorescence intensity values are shown for three batches of CD31+ and CD34+ hiPSC-ECs, HUVECs from three batches (two donors, and two independent batches for one of the donors) and HDMECs from a single donor. Error bars represent ±SD.(E) Immunofluorescent analysis of EC markers VEC, CD31, and vWF on isolated CD34+ and CD31+ hiPSC-ECs (P2). Scale bar represents 100 μm.

Comparative Assessment of Barrier Function and Real-Time Migration of Primary and hiPSC-ECs {#sec2.2}
-------------------------------------------------------------------------------------------

Barrier function and EC migration were assessed by real-time impedance spectroscopy with an integrated assay of electric wound healing, shown schematically in [Figure 2](#fig2){ref-type="fig"}A. We first compared barrier function of ECs derived from several independent hiPSC lines. HDMECs from one donor, HUVECs from two independent donors, and two independent batches for one of the donors were used. Primary cells had comparable population doubling times based on data from the cell provider thus avoiding possible differences in growth rate affecting function. Importantly, we found that barrier function of SeV UiPSC and FiPSC-derived CD31 + ECs was very similar ([Figures 2](#fig2){ref-type="fig"}B and 2C). However, barrier function of CD34+ hiPSC-ECs isolated on day 6, compared with ECs isolated at day 10, was significantly lower compared with CD31+ hiPSC-ECs derived from two independent (isogenic) clones of one line, as well as another independent FiPSC line ([Figures 2](#fig2){ref-type="fig"}B and 2C). In addition, we further investigated barrier function of different batches of CD31+ and CD34+ hiPSC-ECs. We found that independent batches of CD31+ hiPSC-ECs isolated from three SeV hiPSC lines were comparable, with no significant variation among the batches ([Figures S2](#mmc1){ref-type="supplementary-material"}A--S2C). On the other hand, CD34+ hiPSC-ECs (day 6) had higher batch-to-batch variability ([Figure S2](#mmc1){ref-type="supplementary-material"}D). Very little variation across primary ECs was observed ([Figure S2](#mmc1){ref-type="supplementary-material"}E). Thus, ECIS-based assessment of barrier function of hiPSC-ECs is a useful and reproducible quality control assay, particularly in assessing ECs derived from independent hiPSC lines, and independent batches of the same line. Furthermore, CD31+ hiPSC-ECs that are isolated on day 10 are similar, independent of line, genetic background, or batch, and thus might be the most robust readout of disease phenotype in patient hiPSC-ECs or in drug screening applications. When compared with primary ECs, such as HDMECs and HUVECs, CD31+ hiPSC-ECs exhibited either similar, as in the case of FiPSC-ECs versus HDMECs, or higher barrier when cultured in EGM-2 medium ([Figure S2](#mmc1){ref-type="supplementary-material"}F). This is important, since, in contrast to primary ECs with a limited lifespan, hiPSC-ECs can be derived from any individual in unlimited numbers.Figure 2Comparative Assessment of Barrier Function and Real-Time Migration of Primary and hiPSC-ECs(A) Schematic illustration of ECIS barrier function assessment and real-time migration of hiPSC-ECs.(B) Representative absolute resistance of the EC monolayer in complete EC growth medium is shown. Error bars are shown as ±SD of three to four independent wells from representative biological experiments.(C) Quantification of absolute resistance values at 4,000 Hz in complete EC growth medium. Values are presented as average means from a minimum of three independent biological experiments. Error bars are shown as ±SD of three independent biological experiments. ^∗^p \< 0.01, ^∗∗∗^p \< 0.001.(D) Mean absolute resistance from of the EC monolayer in complete EC growth medium or serum-free medium supplemented with VEGF (75 ng/mL) is shown. Error bars are shown as ±SD of average values from three independent biological experiments.(E) Quantification of absolute resistance at 4,000 Hz of the EC monolayer in complete EC growth medium or serum-free medium supplemented with VEGF (75 ng/mL). Error bars are shown as ±SD of three independent biological experiments. ^∗^p \< 0.05, ^∗∗^p \< 0.001.(F) Mean speed of migration (dC/dt) determined as a change in capacitance at 64,000 Hz over the time after electric wound healing in complete EC growth medium or serum-free medium supplemented with VEGF (75 ng/mL). Error bars are shown as ±SD of average values from three independent biological experiments.(G) Quantification of migration rates determined as a time upon closing the wound (dC/dt\>(−0.1 nF/hr)) of hiPSC-ECs in real-time wound healing assay in EC monolayer in complete EC growth medium or serum-free medium supplemented with VEGF (75 ng/mL). Error bars are shown as ±SD of three independent biological experiments. ^∗^p \< 0.05.

In addition, CD31+ and CD34+ hiPSC-ECs exhibited high sensitivity to VEGF ([Figure 2](#fig2){ref-type="fig"}D). Interestingly, although not observed in primary ECs, hiPSC-ECs cultured in basal serum- and growth factor-free medium exhibited increased barrier characteristics compared with "complete" growth medium containing serum ([Figures 2](#fig2){ref-type="fig"}D and 2E). Supplementation with VEGF (75 ng/mL) significantly decreased the endothelial barrier, and this was comparable with the complete growth culture medium condition. Migration rates in the real-time migration assay were lower in VEGF supplemented medium, compared with complete growth medium ([Figures 2](#fig2){ref-type="fig"}F and 2G). No significant difference was found in migration rates of CD31+ and CD34+ hiPSC-ECs in complete growth medium and VEGF supplemented medium ([Figure 2](#fig2){ref-type="fig"}G). Thus, assessment of both barrier function and migration are useful for validating hiPSC-EC functionality, including quality control of independent EC batches, media formulations, and protocols. Of clinical relevance, the assays could be used to screen for compounds that alleviate or aggravate VEGF sensitivity, an important mechanism underlying disease pathology. Somatic cell source and reprogramming methods tested here did not affect these functional characteristics.

Comparison of Barrier Disruption in Primary and hiPSC-ECs {#sec2.3}
---------------------------------------------------------

Barrier disruption was examined as shown schematically in [Figure 3](#fig3){ref-type="fig"}A. For these experiments, hiPSC-ECs first formed confluent monolayers in complete growth medium, the medium was replaced by EGM-2 for at least 12 hr (which is compatible with the wound healing assay), and then they were serum starved in EBM-2 medium for an additional 2--3 hr, since hiPSC-ECs exhibited very poor responses to known permeability factors in complete growth medium (data not shown). EGM-2 medium was chosen as it is widely used for primary ECs. Surprisingly, we found that neither CD31 + or CD34+ hiPSC-ECs were responsive to histamine ([Figures 3](#fig3){ref-type="fig"}B and 3C). HDMECs, on the other hand, exhibited a very pronounced and rapid drop in barrier resistance as early as 1 min post stimulation. Less prominent decreases were also observed in HUVECs, but this was not significant compared with stimulation with control medium (compound free) ([Figures 3](#fig3){ref-type="fig"}B, 3C, and [S3](#mmc1){ref-type="supplementary-material"}A). Stimulation of hiPSC-ECs with thrombin decreased the endothelial barrier, although only at higher concentrations (0.1 U/mL) ([Figures 3](#fig3){ref-type="fig"}B, 3C, [S3](#mmc1){ref-type="supplementary-material"}B, and S3C). Comparison of CD31+ and CD34+ hiPSC-ECs revealed similar barrier disruption in response to thrombin. Despite the relatively low dosage of thrombin, hiPSC-ECs failed to recover the barrier, in contrast to primary ECs. In summary, we found that hiPSC-ECs responded to higher concentration of thrombin (0.1 U/mL) and were not responsive to histamine at the concentrations that disrupt the barrier in HDMECs (50 μM), or even higher (up to 200 μM, data not shown).Figure 3Comparison of Barrier Disruption in Primary and hiPSC-ECs(A) Schematic illustration of workflow for ECIS barrier disruption assessment.(B) Changes in normalized resistance of the EC monolayer upon stimulation with histamine (50 μM) and thrombin (0.05 U/mL and 0.1 U/mL). Stimulation time point is set as t = 0. Normalized resistance is shown as a representative plot of one representative independent experiment. Error bars are shown as ±SD of three to four independent wells.(C) Quantification of minimal normalized resistance upon stimulation with histamine (50 μM) and thrombin (0.05 U/mL and 0.1 U/mL). Control stimulation with equal volume of medium without the compound is shown in [Figure S3](#mmc1){ref-type="supplementary-material"}. Compound-mediated (filled bars) reduction in barrier function is compared with alteration of barrier upon control stimulation (empty bars). Error bars are shown as ±SD from three (n = 3) independent biological experiments. ^∗^p \< 0.05, ^∗∗^p \< 0.001, ^∗∗∗^p \< 0.0001.

Comparison of Junctional Integrity in Primary and hiPSC-ECs {#sec2.4}
-----------------------------------------------------------

EC barrier function and paracellular permeability are dependent on interaction between proteins that form cell-cell junctions, mainly tight junctions (TJs) and adherens junctions (AJs) ([@bib12], [@bib16]). We therefore examined organization of TJs and AJs in serum-starved hiPSC-ECs and primary ECs before and after 30 min stimulation with thrombin (0.05 U/mL and 0.1 U/mL). This time point was chosen as it coincided with the maximum decrease in barrier function evident in impedance measurements. ECs were stained with zonula occluden-1 (ZO1) and VEC to visualize TJs and AJs, respectively, and counterstained with F-actin to reveal cortical actin and formation of actin stress fibers upon junction disassembly. Primary ECs showed robust responses to thrombin (0.05 and 0.1 U/mL) associated with loss of cortical actin and formation of actin stress fibers with opening of the cell junctions ([Figures 4](#fig4){ref-type="fig"}A, 4B, [S4](#mmc1){ref-type="supplementary-material"}A, and S4B), as expected from impedance measurements. Notably, hiPSC-ECs responded only to higher concentrations of thrombin (0.1 U/mL) ([Figures 4](#fig4){ref-type="fig"}C, 4D, [S4](#mmc1){ref-type="supplementary-material"}C, and S4D). Furthermore, when compared in a quiescent (serum-starved) state, CD31+ hiPSC-ECs showed highly organized TJs and AJs that were similar to those in HDMECs, while CD34+ hiPSC-ECs had less organized TJs and AJs with morphology more similar to that observed in HUVECs.Figure 4Comparison of Junctional Integrity in Primary and hiPSC-ECs(A--D) Junctional integrity in primary cells and hiPSC-ECs was analyzed using tight junctional marker (ZO1) counterstained with F-actin in HUVECs (A), HDMECs (B), CD34+ hiPSC-ECs (C), and CD31+ hiPSC-ECs (D) upon control stimulation with medium only (−) or thrombin (TH; 0.05 U/mL and 0.1 U/mL) for 30 min. Disassembly of cell junctions and reorganization of cortical actin and actin stress fiber formation was observed in HUVECs and HDMECs upon thrombin (0.05 U/mL and 0.1 U/mL) stimulation. CD34+ hiPSC-ECs and CD31+ hiPSC-ECs showed robust response upon thrombin (0.1 U/mL) stimulation. Adherents junctions visualized with VEC and counterstained with F-actin are shown in [Figure S4](#mmc1){ref-type="supplementary-material"}. Representative pictures are shown from experiments performed with three batches of CD31+ and CD34+ hiPSC-ECs, HUVECs from three batches (two donors, and two independent batches for one of the donors), and for HDMECs a single donor. Scale bar represents 50 μm.

Comparison of Inflammatory Response in Primary and hiPSC-ECs {#sec2.5}
------------------------------------------------------------

hiPSC-ECs were first assayed for responses to pro-inflammatory agents, such as tumor necrosis factor alpha (TNFα), lipopolysaccharide, and interleukin 1β (IL1β; [Figure S5](#mmc1){ref-type="supplementary-material"} and data not shown). TNFα and IL1β induced rapid upregulation of E-selectin with peak expression 6 hr post treatment in some but not all of the hiPSC-ECs examined. HUVECs exhibited robust upregulation of E-selectin upon TNFα and IL1β treatment, as expected. Furthermore, ICAM-1 upregulation in hiPSC-ECs was more prominent after 6 hr of TNFα treatment, and comparable with HUVECs. ICAM-1 was similarly induced in hiPSC-ECs and HUVECs 24 hr post treatment with either TNFα or IL1β. Upregulation of VCAM-1 was not observed in hiPSC-ECs, in contrast to HUVECs. All subsequent experiments were performed using TNFα, as it was the most potent pro-inflammatory agent in hiPSC-ECs. CD31+ and CD34+ hiPSC-ECs exhibited similar induction of E-selectin and ICAM-1 6 hr and 12 hr post stimulation, although this was lower than in HUVECs ([Figures 5](#fig5){ref-type="fig"}A--5D). The 12 hr time point was specifically chosen, as it was optimal for pre-stimulation of ECs for leukocyte adhesion studies. In order to investigate whether hiPSC-ECs can be used to study endothelial-leukocyte interactions, we established an assay to assess leukocyte adhesion under flow in a commercial system with eight parallel microchannels. hiPSC-ECs or primary ECs were seeded into the microfluidic channels and leukocyte perfusion was precisely controlled by a microfluidic pump. Adhesion of human leukocytes to ECs was investigated under flow at venous shear stress (0.5 dyn/cm^2^). Leukocytes were perfused for 5 min, followed by additional perfusion for 5 min with culture medium to wash away all non-specifically attached cells. Pre-treatment of ECs with TNFα for 12 hr increased leukocyte adhesion significantly compared with non-treated ECs ([Figure 5](#fig5){ref-type="fig"}E and [Video S1](#mmc2){ref-type="supplementary-material"}). CD31+ and CD34+ hiPSC-ECs were similar with respect to the numbers of adherent leukocytes per field, although HUVECs had significantly higher numbers ([Figure 5](#fig5){ref-type="fig"}F). These data showed that CD31+ and CD34+ hiPSC-ECs exhibit comparable inflammatory responses *in vitro*, and can potentially be used to study leukocyte cell interactions, although perhaps with less adhesion "strength" than HUVECs.Figure 5Comparison of Inflammatory Responses in Primary and hiPSC-ECs(A) FACS analysis of surface expression of E-selectin, ICAM-1, and VCAM-1 in untreated cells (black filled histograms) or after 6 hr of treatment (red filled histograms) with TNFα (10 ng/mL).(B) FACS analysis of surface expression of E-selectin, ICAM-1, and VCAM-1 in untreated cells (blue filled histograms) or after 12 hr of treatment (red filled histograms) with TNFα (10 ng/mL).(C) Quantification of surface expression of E-selectin and ICAM-1 on CD34+ and CD31+ after 6 hr of treatment with TNFα (10 ng/mL). Error bars are shown as ±SD of three independent biological experiments.(D) Quantification of surface expression of E-selectin and ICAM-1 on CD34+ and CD31 + after 12 hr of treatment with TNFα (10 ng/mL). Error bars are shown as ±SD of three independent biological experiments.(E) Assessment of leukocyte adhesion under flow. Representative images of adhesion of leukocytes (green) to non-treated (control) or TNFα-treated (12 hr, 10 ng/mL) CD31+ and CD34+ hiPSC-ECs, and HUVEC. Scale bar represents 250 μm.(F) Quantification of leukocyte adhesion per field to TNFα-treated CD31+ and CD34+ hiPSC-ECs, and HUVEC. Data are shown as ±SD (CD31 +, n = 5; CD34 +, n = 4; HUVEC, n = 2); ns, not significant.

Comparison of Primary and hiPSC-ECs in an *In Vitro* Vasculogenesis Assay {#sec2.6}
-------------------------------------------------------------------------

We next examined the ability of CD31+ and CD34+ hiPSC-ECs to form a two-dimensional vascular plexus *in vitro* compared with primary ECs, as described previously ([@bib9], [@bib24]). We observed that hiPSC-ECs were more sensitive to the source of stromal cells than primary ECs. To identify the most reliable stromal cells to support hiPSC-EC sprouting *in vitro*, we screened several batches of CD31-cells from the differentiating hiPSC cultures (hiPSC-pericytes \[hiPSC-Ps\]; [@bib24]), primary human bone marrow stromal cells (BMSCs), and human cardiac fibroblasts (huCFs). Somewhat unexpectedly, huCFs supported hiPSC-EC sprouting better than other stromal cells ([Figures 6](#fig6){ref-type="fig"}B, [S6](#mmc1){ref-type="supplementary-material"}C, and S6D). By contrast, BMSCs were most potent in supporting sprouting of primary HUVECs and HDMECs compared with CD31-hiPSC-Ps (CD31-hiPSC-P) and huCFs ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B), although they supported sprouting of hiPSC-ECs poorly ([Figures S6](#mmc1){ref-type="supplementary-material"}C and S6D). Therefore, huCFs were selected as the preferred stromal cell to compare hiPSC-ECs and primary ECs. In this assay, we thus co-cultured huCFs with CD31+ and CD34+ hiPSC-ECs, HUVECs, and HDMECs ([Figures 6](#fig6){ref-type="fig"}B--6D). Interestingly, under these conditions, CD31+ hiPSC-ECs formed very dense sprouting networks with total vessel lengths and numbers of junctions significantly higher than CD34+ hiPSC-ECs, HUVECs, or HDMECs ([Figure 6](#fig6){ref-type="fig"}D). CD34+ hiPSC-ECs were more similar to HUVECs and formed denser vascular networks than HDMECs, although these were less organized and had thinner sprouts compared with HUVECs. Since hiPSC-ECs exhibited embryonic-like characteristics and had a more prominent arterial-like phenotype, we also examined expression of the nuclear transcription factor SOX17. We found that SOX17 marked hiPSC-EC nuclei in the co-culture system, but not nuclei, of primary ECs ([Figure 6](#fig6){ref-type="fig"}C). Finally, independent batches of CD31+ and CD34+ hiPSC-ECs were very similar, in agreement with our previous results ([Figure 6](#fig6){ref-type="fig"}D).Figure 6Comparison of Primary and hiPSC-ECs in an *In Vitro* Vasculogenesis Assay(A) Schematic representation of an *in vitro* vasculogenesis assay. hiPSC-derived CD31 + or CD34 + cells are combined with stromal cells (huCFs). The cells are mixed plated into 96-well plates and the EC sprouting network is visualized 10 days after co-culture.(B) Representative immunofluorescent images of an *in vitro* vasculogenesis sprouting assay at day 10 of the co-culture used for quantification of the sprouting network. ECs are visualized with anti-CD31 (white). Automatically stitched images (10× objective, 4 × 4 focus planes) are shown. The images were taken with an automated imaging system with autofocus on CD31. Scale bar represents 1,000 μm.(C) Representative immunofluorescent images of an *in vitro* vasculogenesis sprouting assay at day 10 of the co-culture. ECs are visualized with anti-CD31 (red), SOX17 (white), and DAPI (blue). Higher magnification is shown in the framed area. Scale bar represents 500 μm.(D) Quantification of EC sprouting network at day 10 of the co-culture. Quantification was performed with Angiotool software. The total vessel length and total number of junctions are shown. Automatically stitched images (10× objective, 4 × 4 focus planes) from six co-cultures were used for quantification. Data are shown as ±SD. ^∗∗∗∗^p \< 0.0001.

Comparison of Primary and hiPSC-ECs in an *In Vivo* Vasculogenesis Assay {#sec2.7}
------------------------------------------------------------------------

We next tested the *in vivo* functionality of hiPSC-ECs and their ability to form functional, perfused vessels in a heterotopic *in vivo* differentiation assay, described previously ([@bib31]). We first examined the potential of CD31+ hiPSC-ECs co-transplanted with BMSCs to integrate into vessels *in vivo*. CD31+ hiPSC-ECs were mixed with BMSCs and growth factor-reduced Matrigel in different ratios: 1 million hiPSC-ECs and 1 million BMSCs (1:1), 2 million hiPSC-ECs with 1 million BMSC (2:1), and *vice versa* (1:2). Formation of vascular networks containing red blood cells, indirectly suggesting vascular perfusion, was observed at all cell ratios tested ([Figure S7](#mmc1){ref-type="supplementary-material"}), although, overall, the 2:1 ratio gave the best result and was similar to Matrigel transplants containing a 1:1 ratio of HUVECs and BMSCs. We next compared the *in vivo* potential of CD34+ and CD31+ hiPSC-ECs (2 million cells) co-transplanted with CD31-hiPSC-P (1 million) (2:1 ratio), derived as described previously ([@bib25]). Interestingly, both CD31+ and CD34+ hiPSC-ECs formed perfused vascular networks, as indirectly suggested by the presence of red blood cells on immunohistochemistry (IHC) sections ([Figure 7](#fig7){ref-type="fig"}A). The presence of human ECs was confirmed with human-specific and pan-specific (human and mouse) antibody against CD31 ([Figures 7](#fig7){ref-type="fig"}B and 7C). Vascular density appeared higher in the Matrigel plugs containing CD34 + cells compared with CD31 + cells, although this was not statistically significant ([Figures 7](#fig7){ref-type="fig"}D and 7E). Therefore, we concluded that both CD31+ and CD34+ hiPSC-ECs can form functional blood vessels *in vivo* although the transplantation conditions and stromal cell source might need further optimization when comparing with primary ECs.Figure 7Comparison of CD31+ and CD34+ hiPSC-ECs in an *In Vivo* Vasculogenesis Assay(A) H&E images of Matrigel plugs. Representative images of Matrigel plugs with CD31+ hiPSC-ECs and CD34+ hiPSC-ECs co-transplanted with CD31-hiPSC-Ps (1:2). Scale bar represents 75 μm.(B and C) Representative images of Matrigel plugs with CD31+ hiPSC-ECs and CD34+ hiPSC-ECs co-transplanted with CD31-hiPSC-Ps. IHC with pan-specific (red) and anti-human (green) CD31 antibody or overlay (orange). Scale bar represents 100 μm.(D) Quantification of vascular density using pan-specific CD31 (pan-CD31) in Matrigel plugs CD31+ hiPSC-ECs and CD34+ hiPSC-ECs co-transplanted with CD31-hiPSC-Ps (n = 3).(E) Quantification of vascular density using human-specific CD31 (hu-CD31) in Matrigel plugs CD31+ hiPSC-ECs and CD34+ hiPSC-ECs co-transplanted with CD31-hiPSC-Ps (n = 3).

Discussion {#sec3}
==========

Since the initial discovery of hiPSCs, directed differentiation protocols to form specific cell types in defined conditions have significantly improved. With regard to ECs, many protocols have been developed that result in fairly high percentages of ECs that vary from 30% to 80% of the differentiated cell population ([@bib5], [@bib28], [@bib39]). Furthermore, defined matrices, such as recombinant vitronectin and laminin, have also been used ([@bib20], [@bib39]). ECs can be purified and conveniently cryopreserved for immediate use after thaw in various functional assays ([@bib25]). In the present study, we carried out functional assays on hiPSC-ECs at the same passage 2 (P2), which made the biological replicates highly comparable without the need for internal normalization within the assay, as demonstrated. Nevertheless, despite their potential utility, primary ECs are still preferred to hiPSC-ECs in vascular research and assays, likely due to apparent differences in their developmental and differentiation states. hiPSC-ECs are indeed more similar to embryonic ECs, based on their marker and gene expression profiles ([@bib24], [@bib30], [@bib38]). However, this can have advantages for certain applications, such as screening for embryonic vascular toxicity ([@bib38]), and perhaps modeling tumor vasculature, since it is also considered immature. Recent work by our group and others has focused on differentiating hiPSC to ECs of the more prominent vascular beds and tissue-specific ECs, such as arterial, venous, and cardiac ECs, as well as so-called EC colony-forming cells ([@bib11], [@bib18], [@bib26], [@bib29], [@bib39]). Taken together, these findings contribute to enhancing the value of hiPSC-ECs in imminent applications such as drug discovery and regenerative medicine. However, understanding exactly how hiPSC-ECs are similar to or differ from primary ECs through side-by-side comparisons in standard assays is essential for their wider acceptance. An important first step is to identify conditions that support both primary and hiPSC-ECs. This is preferably based on defined cell culture growth medium; synthetic matrices ([@bib19]); and, as necessary, common stromal cell types in co-culture for vasculogenesis assays. Several groups have investigated the impact of the developmental origin of pericytes and smooth muscle cells on vasculogenesis by HUVECs ([@bib6], [@bib17]). Here, we examined the interaction of hiPSC-ECs with stromal cells and report that they have much more stringent stromal cell requirements. For instance, BMSCs were very poor in supporting of sprouting of hiPSC-ECs compared with HUVECs *in vitro* and to a lesser extent *in vivo*, and different stromal cell to EC ratios might be required for efficient vascularization. Although differences in interaction of hiPSC-ECs and primary ECs with the stromal cells have not been addressed here, this would be of interest in future studies.

Comparison of barrier function and inflammatory responses between ECs differentiated from independent isogenic and non-isogenic (non-integrating/DNA-free) hiPSC lines revealed high similarity between independent EC batches. This demonstrates that hiPSCs are a highly consistent source of donor-specific ECs so that genetically induced changes in these features might be regarded as disease-specific phenotypes even in the absence of an isogenic control. Although we found that CD31+ hiPSC-ECs isolated at day 10 of differentiation were more similar to each other than early CD34+ hiPSC-ECs isolated at day 6, this could be due to slight differences in (dynamic) differentiation states, and variable delays less prominent on day 10. Therefore, despite a shorter differentiation protocol and the highly proliferative state of CD34+ hiPSC-ECs, the longer protocol would be preferred for producing more robust batches of ECs for disease modeling purposes. In addition, examination of barrier function across a wide set of hiPSC-ECs revealed that CD31+ hiPSC-ECs had tighter barriers than either CD34+ hiPSC-ECs or primary ECs, like HUVECs and HDMECs. Unexpectedly, hiPSC-ECs did not respond to histamine, a known barrier-disrupting compound. These data contrast with those previously for hiPSC-ECs ([@bib1]) but were highly consistent between all lines here. However, there was a difference in the timing of barrier reduction: [@bib1] showed a delayed response approximately 30 min to 1 hr post stimulation, which also contrasts with reports of other groups for histamine-mediated decreases in endothelial barrier function ([@bib3], [@bib36], [@bib37]). However, both CD31+ and CD34+ hiPSC-ECs did show a pronounced response to relatively low doses of thrombin (0.1 U/mL), with barrier function significantly and non-reversibly altered. The thrombin concentration used here was also significantly lower compared with a previous report, where 20 U/mL was used ([@bib28]). This may have been dictated by different culture and stimulation conditions but our specific aim was to carry out the assays as would normally be done using primary ECs where both 0.05 and 0.1 U/mL thrombin are reportedly sufficient for barrier disruption. In addition to rapid barrier-disrupting agents (histamine and thrombin), we also found that hiPSC-ECs were very sensitive to VEGF, which resulted in a pronounced decrease in the barrier in all hiPSC-ECs examined. Furthermore, no significant difference was found in migration rates between CD31+ and CD34+ hiPSC-ECs.

Examination of inflammatory responses further revealed that both CD31+ and CD34+ hiPSC-ECs responded to TNFα in a similar manner to HUVECs and were capable of upregulating major pro-inflammatory adhesive receptors, such as E-selectin and ICAM-1. However, no upregulation of VCAM-1 was observed in any hiPSC-ECs examined, in contrast to primary ECs. These data also differ from previous reports ([@bib1], [@bib28], [@bib38]). Primary ECs were also shown to exhibit differential upregulation of VCAM-1, much like ECs from different organs such as different compartments of the kidney vasculature, where there is prominent VCAM-1 expression in arteriolar endothelium but not in glomerular endothelium ([@bib4], [@bib33]). Further examination of leukocyte adhesion under physiological flow revealed that CD31+ and CD34+ hiPSC-ECs were comparable, although less pro-adhesive, than HUVECs. Any inconsistences between ECs could be due to the developmental and tissue identity.

Overall, hiPSC-ECs have a number of advantages as model systems over primary ECs: (1) the possibility to derive large batches with very high numbers of high quality ECs from the same donor, all with the similar features to primary ECs; (2) high barrier functions compared with other peripheral ECs; and (3) inflammatory responses in which ECs and monocytes can be derived (isogenically) from the same donor. Present hurdles for hiPSC-ECs compared with primary ECs include (1) lower expression of pro-inflammatory adhesive receptors, such as E-selectin and lack of VCAM-1 induction; and (2) limited maturity (for instance, with lower expression of vWF, which might be a shortcoming in modeling certain genetic conditions). In the future, we expect the functional assays we have described will be useful in comparing hiPSC-ECs from more advanced differentiation protocols in which cells have more prominent venous- or tissue-specific identities, important in modeling genetic and other diseases associated with particular vascular beds.

In summary, we have provided here comprehensive characterization and line-to-line and batch-to-batch comparisons of hiPSC-ECs. We demonstrated that barrier function and inflammatory responses are highly consistent between different healthy hiPSC-EC lines, and therefore can be considered as a benchmark for standardization of functionality across different lines.

Experimental Procedures {#sec4}
=======================

Details are provided in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

hiPSC Lines and Maintenance {#sec4.1}
---------------------------

The following SeV reprogrammed hiPSCs lines were used in this study: FiPSC line generated from fibroblast (FiPSC line LUMC0020iCTRL), as described previously ([@bib40]), and hiPSCs from urine-derived cells (UiPSC lines): LUMC0054iCTRL (additional information available in public databases: <http://hpscreg.eu/cell-line/LUMCi001-A> and <http://hpscreg.eu/cell-line/LUMCi001-A-1>). hiPSCs were cultured on Matrigel-coated plates in mTeSR-1 or recombinant vitronectin-coated plates in TeSR-E8, all from STEMCELL Technologies, according to the manufacturer\'s instructions.

Differentiation of hiPSCs toward ECs {#sec4.2}
------------------------------------

hiPSCs were maintained in mTeSR-1 or mTeSR-E8 and differentiated toward ECs using previously published protocols ([@bib25], [@bib24]).

Characterization of CD34+ and CD31+ hiPSC-ECs {#sec4.3}
---------------------------------------------

Basic characterization of hiPSC-ECs, such as FACS analysis, immunofluorescence, and gene expression analyses, was performed as previously described ([@bib25]).

Assessment of hiPSC-EC Functionality in an *In Vivo* Vasculogenesis Assay {#sec4.4}
-------------------------------------------------------------------------

The Matrigel plug assay was performed as previously described ([@bib31]). Experiments with hiPSC-ECs and BMSCs were carried out in compliance with relevant Italian laws and institutional guidelines for animals and all procedures were Institutional Animal Care and Use Committee approved. Experiments with hiPSC-ECs and CD31-hiPSC-P were approved by the Leiden University Medical Center animal experimental committee and the Commission Biotechnology in Animals of the Dutch Ministry of Agriculture.

Statistical Analysis {#sec4.5}
--------------------

Statistical analyses were conducted with GraphPad Prism 7 software. One-way ANOVA with Tukey\'s multiple comparison for the analysis of three or more groups or Mann-Whitney test for analysis of two groups were used. The data are reported as mean ± SD.
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